Alkermes Pharma Ireland Limited

Mural Oncology, Inc.

Jared Lopes

Heather C Losey

Raymond J Winquist

Lei Sun

The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (T) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.

Compositions and methods for subcutaneous administration of cancer immunotherapy

The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.

Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors

The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).

Growing community of inventors

Wilmington, MA, United States of America

Jared Lopes